Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.

Deeb LC, Dulude H, Guzman CB, Zhang S, Reiner BJ, Piché CA, Pradhan S, Zhang XM.

Pediatr Diabetes. 2018 Aug;19(5):1007-1013. doi: 10.1111/pedi.12668. Epub 2018 Mar 22.

PMID:
29512902
2.

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.

Seaquist ER, Dulude H, Zhang XM, Rabasa-Lhoret R, Tsoukas GM, Conway JR, Weisnagel SJ, Gerety G, Woo VC, Zhang S, Carballo D, Pradhan S, Piché CA, Guzman CB.

Diabetes Obes Metab. 2018 May;20(5):1316-1320. doi: 10.1111/dom.13278. Epub 2018 Mar 22.

3.

Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial.

Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, Carballo D, Triest M, Zhang MX, Zhang S, Tafreshi M, Sicard E.

Diabetes Obes Metab. 2018 Mar;20(3):646-653. doi: 10.1111/dom.13134. Epub 2017 Nov 19.

4.

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.

Yale JF, Dulude H, Egeth M, Piché CA, Lafontaine M, Carballo D, Margolies R, Dissinger E, Shames AR, Kaplowitz N, Zhang MX, Zhang S, Guzman CB.

Diabetes Technol Ther. 2017 Jul;19(7):423-432. doi: 10.1089/dia.2016.0460. Epub 2017 May 30.

5.

Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. No abstract available.

6.

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.

Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Apr;39(4):555-62. doi: 10.2337/dc15-1606. Epub 2016 Feb 16.

7.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17.

8.

Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.

Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6018-22.

9.

Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding.

Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R.

Biochem Biophys Res Commun. 2006 Jul 21;346(1):358-66. Epub 2006 Jun 2.

PMID:
16759641
10.

Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.

Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R.

Anticancer Drugs. 2006 Apr;17(4):429-38.

PMID:
16550001
11.

A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.

Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, Jewett MA, Narod SA.

J Urol. 2006 Apr;175(4):1291-7.

PMID:
16515983
12.

A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis.

Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R.

Clin Exp Metastasis. 2005;22(5):429-39.

PMID:
16283486
13.

Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer.

Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, Fenemore J, Irvine A, Sereda K, Dulude H.

Clin Prostate Cancer. 2005 Sep;4(2):91-9.

PMID:
16197609
14.

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

Trudeau M, Stuart G, Hirte H, Drouin P, Plante M, Bessette P, Dulude H, Lebwohl D, Fisher B, Seymour L.

Gynecol Oncol. 2002 Feb;84(2):327-31.

PMID:
11812095
15.

A phase II trial of mitomycin, ifosfamide and cisplatin in recurrent carcinoma of the cervix.

Trudeau M, Seymour R, Stanimir G, Souhami L, Arthur L, Dulude H, Gallant G, Leyland-Jones B.

Int J Gynecol Cancer. 2000 May;10(3):207-211.

PMID:
11240676
16.

Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas.

Goss P, Stewart AK, Couture F, Klasa R, Glück S, Kaizer L, Burkes R, Charpentier D, Palmer M, Tye L, Dulude H.

Leuk Lymphoma. 1999 Jul;34(3-4):295-304.

PMID:
10439366
17.

A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.

Gelmon KA, Tolcher A, O'Reilly S, Campbell C, Bryce C, Shenkier T, Ragaz J, Ayers D, Nakashima L, Rielly S, Dulude H.

Ann Oncol. 1998 Nov;9(11):1247-9.

PMID:
9862057
18.

Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.

Bjarnason GA, Cripps C, Goel R, Fine S, Oza AM, Skillings JR, Kerr I, Germond CJ, Moore MJ, Maroun JA, Franssen E, Dulude H.

Am J Clin Oncol. 1998 Dec;21(6):537-42.

PMID:
9856651
19.

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer.

Glück S, Germond C, Lopez P, Cano P, Dorreen M, Koski T, Arnold A, Dulude H, Gallant G.

Eur J Cancer. 1998 Jun;34(7):1008-14.

PMID:
9849448
20.

In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine.

Obrocea MM, Nassim MA, Molepo MJ, Shirazi FH, Gallant G, Dulude H, Vincent MD, Stewart DJ, Goel R.

Oncol Rep. 1998 Nov-Dec;5(6):1493-8.

PMID:
9769394
21.

Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.

Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, Hanson J, Summers N, Brown B, Dulude H, Gallant G.

Cancer Prev Control. 1998 Apr;2(2):74-8.

PMID:
9765767
22.

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).

Warner E, Goel R, Chang J, Chow W, Verma S, Dancey J, Franssen E, Dulude H, Girouard M, Correia J, Gallant G.

Br J Cancer. 1998 Jun;77(12):2376-80.

23.

A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer.

Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H.

Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1107-11.

PMID:
9392551
24.

Concurrent use of multiple chemotherapy resistance modulators with etoposide in patients with resistant malignancies.

Stewart D, Goel R, Cripps M, Yau J, Huan S, Tomiak E, Davies R, Dulude H, Gallant G.

Int J Oncol. 1997 Oct;11(4):709-16.

PMID:
21528265
25.

Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer.

Evans WK, Earle CC, Stewart DJ, Dahrouge S, Tomiak E, Goss G, Logan D, Goel R, Gertler SZ, Dulude H.

Lung Cancer. 1997 Aug;18(1):83-94.

PMID:
9268950
26.

Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.

Stewart DJ, Tomiak EM, Goss G, Gertler SZ, Logan D, Huan S, Yau J, Dulude H, Evans WK.

Lung Cancer. 1996 Aug;15(1):115-23.

PMID:
8865129
29.

Synthesis and anti-HIV activity of new urea and nitrosourea derivatives of diamino acids.

Dulude H, Salvador R, Gallant G.

Bioorg Med Chem. 1995 Feb;3(2):151-60.

PMID:
7796048
30.

Supplemental Content

Loading ...
Support Center